夏科雷登氏结晶蛋白(CLC)重组蛋白

YB387Mu022
Recombinant Charcot Leyden Crystal Protein (CLC)
Organism Species: Homo sapiens (Human)
Instruction manual
FOR IN VITRO USE AND RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES
10th Edition (Revised in Jan, 2014)
夏科雷登氏结晶蛋白(CLC)重组蛋白[ PROPERTIES ]
Residues: Ser2~Arg142
Tags: N-terminal His-Tag
Accession: Q05315
Host: E. coli
Subcellular Location: Cytoplasmic granule.
Purity: >90%
Endotoxin Level: <1.0EU per 1μg
(determined by the LAL method).
Formulation: Supplied as lyophilized form in 20mM Tris,
1夏科雷登氏结晶蛋白(CLC)重组蛋白50mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT,

0.01% sarcosyl, 5% trehalose, and preservative.
Predicted isoelectric point: 6.8
Predicted Molecular Mass: 17.6kDa
Applications: SDS-PAGE; WB; ELISA; IP.
(May be suitable for use in other assays to be determined by the end user.)
[ USAGE ]
Reconstitute in sterile ddH2O.
[ STORAGE AND STABILITY ]
Storage: Avoid repeated freeze/thaw cycles.
Store at 2-8
oC for one month.
Aliquot and store at -80oC for 12 months.
Stability Test: The thermal stability is described by the loss rate of the target
protein. The loss rate was determined by accelerated thermal degradation test,
that is, incubate the protein at 37oC for 48h, and no obvious degradation and
precipitation were observed. (Referring from China Biological Products Standard,
which was calculated by the Arrhenius equation.) The loss of this protein is less
than 5% within the expiration date under appropriate storage condition.
夏科雷登氏结晶蛋白(CLC)重组蛋白[ SEQUENCES ]
The sequence of the target protein is listed below.
SLLPVPYTE AASLSTGSTV TIKGRPLACF LNEPYLQVDF HTEMKEESDI VFHFQVCFGR
RVVMNSREYG AW KQQVESKN MPFQDGQEFE LSISVLPDKY QVMVNGQSSY
TFDHRIKPEA VKMVQVWRDI SLTKFNVSYL KR
[ REFERENCES ]
1. Ackerman S.J., et al. (1993) J. Immunol. 150:456-468.
2. Mastrianni D.M., et al. (1992) Genomics 13:240-242.
3. Dyer K.D., et al. (1997) Genomics 40:217-221.
4. Kubach J., et al. (2007) Blood 110:1550-1558.